hno:
COVID Outbreak Sparked by Fully Vaccinated Patient Challenges Vaccine-Induced Herd Immunity Theory
COVID spread rapidly by a fully vaccinated patient to fully vaccinated staff, patients and family members — despite a 96% vaccination rate and use of full personal protective equipment. Five patients died and nine had severe cases.
COVID spread rapidly by a fully vaccinated patient to fully vaccinated staff, patients and family members — despite a 96% vaccination rate and use of full personal protective equipment. Five patients died and nine had severe cases.
not too shabby.... a year ago running a fledgling big pharma company that could never get a drug approved by the FDA. A year later still running a big pharma company that has never gotten a drug approved by the FDA 
emergency authorization kills well, errrrr, pays well
Moderna founders debut on Forbes’ list of 400 richest Americans
The success of Moderna’s COVID-19 vaccine has minted three new billionaires who had early stakes in the biotech startup, leading to their debut on this year’s Forbes list of the 400 richest people in the US.
Moderna co-founder and chairman Noubar Afeyan along with fellow co-founder and Massachusetts Institute of Technology professor Robert Langer both made the list, with estimated net worths of $3.7 billion and $3.5 billion, respectively.
Timothy Springer, a Harvard Medical School professor and early Moderna investor, also debuted on the list with a net worth of $4.4 billion, according to Forbes. The company has previously said it expects to make at least $19.2 billion in sales of its COVID-19 vaccine. Moderna’s successful development of the vaccine propelled it out of the world of biotech startup obscurity and landed huge gains for shareholders.The stock is up more than 189 percent since Jan. 1, and over 300 percent higher compared with a year ago.
Since its initial public offering at $22 per share in 2018, the company’s stock is up more than 1,200 percent. It was last seen trading at $297.50 a share. The company’s now valued at more than $120 billion, larger than General Electric. Its a massive market valuation for a firm whose revenue is made up of just one product.
emergency authorization kills well, errrrr, pays well
Moderna founders debut on Forbes’ list of 400 richest Americans
The success of Moderna’s COVID-19 vaccine has minted three new billionaires who had early stakes in the biotech startup, leading to their debut on this year’s Forbes list of the 400 richest people in the US.
Moderna co-founder and chairman Noubar Afeyan along with fellow co-founder and Massachusetts Institute of Technology professor Robert Langer both made the list, with estimated net worths of $3.7 billion and $3.5 billion, respectively.
Timothy Springer, a Harvard Medical School professor and early Moderna investor, also debuted on the list with a net worth of $4.4 billion, according to Forbes. The company has previously said it expects to make at least $19.2 billion in sales of its COVID-19 vaccine. Moderna’s successful development of the vaccine propelled it out of the world of biotech startup obscurity and landed huge gains for shareholders.The stock is up more than 189 percent since Jan. 1, and over 300 percent higher compared with a year ago.
Since its initial public offering at $22 per share in 2018, the company’s stock is up more than 1,200 percent. It was last seen trading at $297.50 a share. The company’s now valued at more than $120 billion, larger than General Electric. Its a massive market valuation for a firm whose revenue is made up of just one product.
Question #1 = why was DARPA, a military agency that makes weapons like GPS-directed drones and stealth bombers, funding Moderna a pharmaceutical company? bioweapons program?
Question #2 = why did Moderna fail to disclose this funding which is illegal for any company filing a patent application? Despite the majority of Moderna's 126 patents having some federal funding not a single one of these patent applications disclosed DARPA awards
Question #3 = why was DARPA's chief of biodefense, Michael Callahan, an ex-USSR bioweapons lab expert who increased biodefense funding at DARPA from $60M to $260M in just 6 years, a frequent visitor to the famous Level 4 Wuhan lab as far back as 2017 and through the early days of the Wuhan outbreak?
Question #4 = why was Callahan put on leave when, as a coronavirus expert, suggested that H2 receptor Famotidine (aka Pepcid) was a low-cost and widely available treatment after examining 6000 patient records from Wuhan?
Question #2 = why did Moderna fail to disclose this funding which is illegal for any company filing a patent application? Despite the majority of Moderna's 126 patents having some federal funding not a single one of these patent applications disclosed DARPA awards
Question #3 = why was DARPA's chief of biodefense, Michael Callahan, an ex-USSR bioweapons lab expert who increased biodefense funding at DARPA from $60M to $260M in just 6 years, a frequent visitor to the famous Level 4 Wuhan lab as far back as 2017 and through the early days of the Wuhan outbreak?
Question #4 = why was Callahan put on leave when, as a coronavirus expert, suggested that H2 receptor Famotidine (aka Pepcid) was a low-cost and widely available treatment after examining 6000 patient records from Wuhan?
